Description
Adverse drug reactions are the fourth-leading cause of death in the U.S. and pharmacogenomic testing offers the hope of being able to identify those at risk of reacting adversely to a specific drug or dosage.  A patient’s phenotype for metabolizing certain types of drugs (poor, intermediate, extensive, or ultra rapid metabolizer) largely depends on genetic mutations within the Cytochrome P450 enzyme family.  Predicting this genotype is critical for determining proper drug dosage, but screening for all known mutations can be labor intensive.  xMAP technology enables multiplex genotyping of up to 100 unique alleles in a single sample well, boosting a laboratory’s productivity and increasing the amount of  data obtained without increasing labor and costs.

Tests available from:

Luminex Molecular Diagnostics